The Impact of Organised Screening Programs on Breast Cancer Stage at Diagnosis for Canadian Women Aged 40-49 and 50-59.

breast cancer clinical practice prevention recommendations registries screening mammography stage shift

Journal

Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503

Informations de publication

Date de publication:
09 08 2022
Historique:
received: 23 06 2022
revised: 28 07 2022
accepted: 03 08 2022
entrez: 25 8 2022
pubmed: 26 8 2022
medline: 27 8 2022
Statut: epublish

Résumé

The relationship between Canadian mammography screening practices for women 40−49 and breast cancer (BC) stage at diagnosis in women 40−49 and 50−59 years was assessed using data from the Canadian Cancer Registry, provincial/territorial screening practices, and screening information from the Canadian Community Health Survey. For the 2010 to 2017 period, women aged 40−49 were diagnosed with lesser relative proportions of stage I BC (35.7 vs. 45.3%; p < 0.001), but greater proportions of stage II (42.6 vs. 36.7%, p < 0.001) and III (17.3 vs. 13.1%, p < 0.001) compared to women 50−59. Stage IV was lower among women 40−49 than 50−59 (4.4% vs. 4.8%, p = 0.005). Jurisdictions with organised screening programs for women 40−49 with annual recall (screeners) were compared with those without (comparators). Women aged 40−49 in comparator jurisdictions had higher proportions of stages II (43.7% vs. 40.7%, p < 0.001), III (18.3% vs. 15.6%, p < 0.001) and IV (4.6% vs. 3.9%, p = 0.001) compared to their peers in screener jurisdictions. Based on screening practices for women aged 40−49, women aged 50−59 had higher proportions of stages II (37.2% vs. 36.0%, p = 0.003) and III (13.6% vs. 12.3%, p < 0.001) in the comparator versus screener groups. The results of this study can be used to reassess the optimum lower age for BC screening in Canada.

Identifiants

pubmed: 36005182
pii: curroncol29080444
doi: 10.3390/curroncol29080444
pmc: PMC9406663
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5627-5643

Références

J Natl Cancer Inst Monogr. 1997;(22):87-92
pubmed: 9709282
Cancer. 1997 Dec 1;80(11):2091-9
pubmed: 9392331
JAMA Surg. 2018 Jun 1;153(6):594-595
pubmed: 29516087
Cancer. 2020 Jul 1;126(13):2971-2979
pubmed: 32390151
CMAJ. 1992 Nov 15;147(10):1477-88
pubmed: 1423088
Curr Oncol. 2014 Dec;21(6):281-93
pubmed: 25489255
Eur J Public Health. 2012 Jun;22(3):413-8
pubmed: 21746751
Breast Cancer Res Treat. 1997 Sep;45(3):263-70
pubmed: 9386870
Health Rep. 1996 Autumn;8(2):29-37(Eng); 31-40(Fre)
pubmed: 9110963
Br J Cancer. 2004 Mar 22;90(6):1138-43
pubmed: 15026792
J Clin Oncol. 2016 Sep 20;34(27):3308-14
pubmed: 27480155
Health Rep. 2021 Sep 15;32(9):14-26
pubmed: 34523870
Breast Cancer Res Treat. 2021 May;187(1):295-297
pubmed: 33770312
Eur J Cancer. 2022 Jul 12;173:1-9
pubmed: 35839596
J Am Coll Radiol. 2013 May;10(5):317-9; discussion 323
pubmed: 23542028
J Med Screen. 2022 Mar;29(1):7-11
pubmed: 34812692
Can Fam Physician. 2020 May;66(5):321-326
pubmed: 32404449
Curr Oncol. 2022 May 30;29(6):3894-3910
pubmed: 35735420
Cancer. 2019 Feb 15;125(4):515-523
pubmed: 30411328
JAMA. 1971 Mar 15;215(11):1777-85
pubmed: 5107709
Am Health Drug Benefits. 2016 Feb;9(1):23-32
pubmed: 27066193
N Engl J Med. 2012 Nov 22;367(21):1998-2005
pubmed: 23171096
Curr Oncol. 2016 Dec;23(6):e615-e625
pubmed: 28050152
J Natl Cancer Inst. 2015 Mar 30;107(6):djv048
pubmed: 25825511
Ann Oncol. 2011 Aug;22(8):1726-35
pubmed: 21252058
Ann Oncol. 2021 Aug;32(8):1015-1024
pubmed: 34102253
Can Assoc Radiol J. 2022 Feb;73(1):90-100
pubmed: 34279132
J Natl Cancer Inst. 2005 Aug 17;97(16):1195-203
pubmed: 16106024
J Natl Cancer Inst. 2014 Oct 01;106(11):
pubmed: 25274578
CMAJ Open. 2018 Feb 8;6(1):E77-E86
pubmed: 29440151
BMJ. 1988 Oct 15;297(6654):943-8
pubmed: 3142562
Ann Intern Med. 2021 Dec;174(12):1637-1646
pubmed: 34662151
Lancet. 1990 Feb 3;335(8684):241-6
pubmed: 1967717
AJR Am J Roentgenol. 2018 Feb;210(2):264-270
pubmed: 29064760
N Engl J Med. 2007 Jan 18;356(3):227-36
pubmed: 17229950
J Am Coll Radiol. 2020 Oct;17(10):1269-1275
pubmed: 32473894
Lancet. 1985 Apr 13;1(8433):829-32
pubmed: 2858707
Eur J Public Health. 2022 Aug 1;32(4):630-635
pubmed: 35732293
J Med Screen. 2012;19 Suppl 1:42-56
pubmed: 22972810
Cancer Epidemiol Biomarkers Prev. 2004 Feb;13(2):225-34
pubmed: 14973097
Semin Oncol. 2009 Jun;36(3):237-49
pubmed: 19460581
BMJ. 2014 Feb 11;348:g366
pubmed: 24519768
CMAJ. 1992 Nov 15;147(10):1459-76
pubmed: 1423087
Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1699-705
pubmed: 19505902
CMAJ. 2011 Nov 22;183(17):1991-2001
pubmed: 22106103
Breast Cancer Res Treat. 2021 Jan;185(2):507-515
pubmed: 33064230
Cancers (Basel). 2019 Apr 08;11(4):
pubmed: 30965658
Cancer. 1995 Apr 1;75(7):1619-26
pubmed: 8826919
J Med Screen. 2015 Dec;22(4):194-200
pubmed: 26081449
CMAJ. 2018 Dec 10;190(49):E1441-E1451
pubmed: 30530611
Cancer. 1994 Jul 1;74(1 Suppl):222-7
pubmed: 8004590
J Prim Care Community Health. 2022 Jan-Dec;13:21501327211058322
pubmed: 35068237
CMAJ. 2022 May 2;194(17):E601-E607
pubmed: 35500919
J Natl Cancer Inst. 2014 Sep 12;106(10):
pubmed: 25217577

Auteurs

Anna N Wilkinson (AN)

Department of Family Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8L6, Canada.

Jean-Michel Billette (JM)

Centre for Population Health Data at Statistics Canada, Ottawa, ON K1A 0T6, Canada.

Larry F Ellison (LF)

Centre for Population Health Data at Statistics Canada, Ottawa, ON K1A 0T6, Canada.

Michael A Killip (MA)

School of Medicine, University of Limerick, V94 T9PX Limerick, Ireland.

Nayaar Islam (N)

Clinical Epidemiology Program, The Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada.

Jean M Seely (JM)

Department of Radiology, The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON K1H 8L6, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH